Enteropathy-Associated T-Cell Lymphoma clinical trials
The registry lists 32 studies for Enteropathy-Associated T-Cell Lymphoma across more than 10 countries. 5 are recruiting or about to start. 4 of them are mainly about Enteropathy-Associated T-Cell Lymphoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06.
Get an email when these change. Save the Enteropathy-Associated T-Cell Lymphoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
M.D. Anderson Cancer Center (3) · City of Hope Medical Center (3) · National Cancer Institute (NCI) (3) · Mayo Clinic (3) · Ruijin Hospital (2) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (2) · Eric Jacobsen, MD (1) · Washington University School of Medicine (1)
What is being tested here
Drugs under test in Enteropathy-Associated T-Cell Lymphoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Azacitidine | 2 | 0 | 3 |
| Pralatrexate | 1 | 0 | 2 |
| Duvelisib | 1 | 0 | 2 |
| Cc-486 | 1 | 0 | 2 |
| Dibotatug | 1 | 0 | 1 |
| Brentuximab Vedotin | 0 | 0 | 4 |
| Doxorubicin | 0 | 0 | 2 |
| Etoposide | 0 | 0 | 2 |
| Romidepsin | 0 | 0 | 2 |
| Vorinostat | 0 | 0 | 2 |
Drug classes tested here Antimetabolites 2 open · HDAC inhibitors 5
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Dec 2026A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas · Dren Bio
- May 2027Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma · Alliance for Clinical Trials in Oncology
Who these studies take
Of the 4 Enteropathy-Associated T-Cell Lymphoma studies recruiting now, 4 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (25%) | 1 (25%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 4 (100%) | 4 (100%) |
| 40 | 4 (100%) | 4 (100%) |
| 50 | 4 (100%) | 4 (100%) |
| 65 | 4 (100%) | 4 (100%) |
| 75 | 4 (100%) | 4 (100%) |
| 85 | 4 (100%) | 4 (100%) |
Across all 32 studies, recruiting or not: 19% stop at 75 or younger and 9% at 65; 9% take children; 0% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting1
Studies
Recruiting first, then most recently updated. Showing 32 of 32. search them.
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaRecruitingNCT04803201Phase 21 country
- Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell LymphomaRecruitingNCT07691450Phase 11 country
- A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasRecruitingNCT05475925Phase 1/29 countries
- A Registry for People With T-cell LymphomaRecruitingNCT059781411 country
- Go-CHOP in de Novo Intestinal T-cell Lymphoma PatientsNot yet recruitingNCT06701344Phase 2
- Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell LymphomaActive, not recruitingNCT03113500Phase 22 countries
- Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell LymphomasActive, not recruitingNCT03598998Phase 1/21 country
- A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)SuspendedNCT07055477Phase 11 country
- Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesSuspendedNCT05377827Phase 11 country
- Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D InsufficiencyActive, not recruitingNCT01787409Not applicable1 country
- Tazemetostat Plus CHOP in 1L T-cell LymphomaWithdrawnNCT06692452Phase 2
- A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)CompletedNCT02588651Phase 21 country
- CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.CompletedNCT03217643Phase 21 country
- Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's LymphomaCompletedNCT02561273Phase 1/21 country
- Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaWithdrawnNCT04795869Phase 21 country
- T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing LymphomasCompletedNCT03049449Phase 11 country
- Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell LymphomaWithdrawnNCT04639843Phase 11 country
- CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label StudyStatus unknownNCT04480788Phase 11 country
- MAgnetic Resonance Imaging in COeliac DiseaseCompletedNCT025512891 country
- Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT03075553Phase 21 country
- CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCLStatus unknownNCT02533700Phase 21 country
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable1 country
- Study of MLN8237 in Participants With Advanced Hematological MalignanciesCompletedNCT00697346Phase 11 country
- Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT01590732Phase 11 country
- CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II StudyStatus unknownNCT01719835Phase 21 country
- CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell LymphomaStatus unknownNCT01746992Phase 41 country
- Comparison Between Axial- and Lateral-viewing Capsule Endoscopy in Celiac DiseaseStatus unknownNCT03095573Not applicable1 country
- CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and LymphomaStatus unknownNCT02742727Phase 1/21 country
- Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory LymphomaTerminatedNCT00671112Phase 11 country
- SAHA + CHOP in Untreated T-cell Non-Hodgkin's LymphomaCompletedNCT00787527Phase 1/21 country
- Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell LymphomaCompletedNCT00901147Phase 23 countries
- Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's LymphomaTerminatedNCT00810576Phase 21 country